Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCET: Neoadjuvant Chemo-Endocrine Therapy in ER+/HER2- Breast Cancer
NCT02980965Phase 3Completed
- Sponsor
- Fudan University
- Start
- May 2013
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of letrozole, leuprorelin extended-release injection in estrogen receptor-positive breast cancer (ER+), sponsored by Fudan University. Started May 2013; status: completed.
02
Drugs
letrozoleleuprorelin extended-release injection
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT02980965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980965.